The Breakthrough List

May 1, 2012

NOVEL BREAKTHROUGH CANCER THERAPEUTICS IN US PIPELINE
The “Breakthrough List”
General pharmaceuticals, targeted pharmaceuticals, biologics, and therapeutic vaccines listed herein are investigational drugs yet to be fully proven.   Fight to Live has identified these compounds for potential “breakthrough” status because they are either or both scientifically and clinically promising to significantly impact cancer care, options and outcomes.  Risk and benefits are not fully established.  Access is limited to those who qualify for and are accepted into available clinical trials and who are willing to assume unknown risks and outcomes.  This list does not include all therapeutics that may also be considered breakthroughs.  This list is also periodically updated, and only reflects the opinion of Fight to Live Coalition. Recommendations for the Breakthrough List will be considered by the Fight to Live Scientific Board.

Solid Tumors

Kidney Cancer

DendreonCarbonic Anhydrase IX CA9
Seattle Genetics SGN-75
CelldexCDX-014
CelldexCDX-1135

Prostate Cancer

MedivationMDV3100
Bristol-Meyers SquibbIpilimumab
ExelixisXL184
Seattle Genetics / AstellasASG-5ME

Colon, Colorectal Cancer

DendreonCarbonic Anhydrase IX (CA9)
DendreonCarcinoembryonic Antigen (CEA)
GenentechDulanermin (rhApo2L/TRAIL)
Seattle Genetics SGN-75
Plexxikon PLX4032

Breast Cancer

DendreonCarcinoembryonic Antigen (CEA)
GenentechPI3 Kinase Inhibitor (GDC-0941)
Sanofi-Aventis Iniparib
Exelixis XL184
Exelixis XL147
Celldex CDX-011
Plexxikon PLX3397

Lung Cancer

Glaxo-Smith-KlineMAGE-A3
DendreonCarcinoembryonic Antigen (CEA)
GenentechPI3 Kinase Inhibitor (GDC-0941)
PfizerCrizotinib
Avila TherapeuticsC01686
Exelixis XL147
Exelixis XL765
Bristol-Meyers Squibb Ipilimumab

Bladder Cancer

DendreonDN24-02
CelldexCDX-1307

Cervical Cancer

Dendreon Carbonic Anhydrase IX (CA9)

Ovarian Cancer

ExelixisXL184
CelldexCDX-014

Stomach / Gastro/ Esoph Cancers

ExelixisXL184
MicrometMT111

Pancreatic Cancer

Pharmacyclics PCI-27483
Seattle Genetics ASG-5ME
Exelixis XL184

Melanoma

MannkindMKC1106-MT
ExelixisXL184

Head & Neck Cancers

Takeda Millenium Panitimumab (Vectibix)

Brain/Glioblastoma

CelldexCDX 110 - Rindopepimut
Pharmacyclics Motexafin Gadolinium
ExelixisXL184
ExelixisXL765

Bone/Sarcoma

ZiopharmPalifosfamide
PharmacyclicsPCI-24781

Thyroid Cancer

ExelixisXL184

Diverse Solid Tumors

DendreonD-3263 HCl
GenentechAkt Inhibitor (GDC-0068)
GenentechMEK Inhibitor (GDC-0623)
GenentechAnti-EGFL7 MAb
GenentechAnti-NRP1 MAb
GenentechIAP Antagonist (GDC-0917)
GenentechPI3 Kinase Inhibitor (GDC-0941)
GenentechNavitoclax (ABT-263)
RegulusAnti-MiR-34
ExelixisXL184
ExelixisXL147
ExelixisXL765
ExelixisXL413
ExelixisXL888
CelldexCDX-1401
MicrometMT110
MicrometBiTE
Amgen/Biovex Oncovex

Hematologic Cancers

Leukemia / Lymphoma

PharmacyclicsPCI-32765
PharmacyclicsPCI-24781
GenentechNavitoclax (ABT-263)
Avila Therapeutics AVL 292
MicrometMT103
Seattle Genetics SGN-35
Seattle Genetics SGN-75
Seattle Genetics / GenentechSGN-40
GenentechIAP Antagonist (GDC-0917)
GenentechPI3 Kinase Inhibitor (GDC-0941)
CelldexCDX-1127
ZiopharmDarinasparsin

Multiple Myeloma

MerckVorinostat
GenentechAnti FGFR3 MAb
Seattle Genetics SGN-40
MicrometBiTE
ZiopharmDarinasparsin

Diverse Hematologic Cancers

CelgenePomalidomide
GenentechAnti-CD22 ADC
GenentechNavitoclax (ABT-263)
IncyteJAK
Seattle Genetics SGN-19A

 

Donate Now

Your contribution will help Fight to Live
continue to drive public awareness, grow
the coalition, and organize activities and
actions that members can participate in.
Contributions will also help continue its
efforts and advocacy in Washington DC,
informing congressional staff of the dire
need for continual investment in new
therapies alongside a more streamlined,
efficient approval process.